Clinical Trial Update: Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI... [Phase 2]

View source ↗

Summary

Phase 2 randomized trial evaluating adoptive cell therapy with tumor-infiltrating lymphocytes plus interleukin-2 in metastatic melanoma, with or without 12 Gy t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Interleukin-2 (interleukin-2)
• Tumor-infiltrating lymphocytes (TIL) therapy

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Melanoma, Skin Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-12-19